<bill session="117" type="s" number="1123" updated="2023-01-11T13:49:21Z">
  <state datetime="2021-04-14">REFERRED</state>
  <status>
    <introduced datetime="2021-04-14"/>
  </status>
  <introduced datetime="2021-04-14"/>
  <titles>
    <title type="display">PING Act</title>
    <title type="official" as="introduced">A bill to preserve non-interference under the Medicare part D Prescription Drug Benefit program.</title>
    <title type="short" as="introduced">PING Act</title>
    <title type="short" as="introduced">Preserving Innovation for the Next Generation Act</title>
  </titles>
  <sponsor bioguide_id="B001243"/>
  <cosponsors>
    <cosponsor bioguide_id="G000386" joined="2021-04-22"/>
  </cosponsors>
  <actions>
    <action datetime="2021-04-14">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2021-04-14" state="REFERRED">
      <text>Read twice and referred to the Committee on Finance.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSFI" name="Senate Finance" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Competition and antitrust"/>
    <term name="Health care costs and insurance"/>
    <term name="Inflation and prices"/>
    <term name="Medicare"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2021-09-14T13:18:03Z" status="Introduced in Senate">Preserving Innovation for the Next Generation Act or the PING Act

This bill expresses the sense of the Senate that the current restrictions prohibiting the Centers for Medicare &amp; Medicaid Services from negotiating the prices or establishing a formulary for drugs under the Medicare prescription drug benefit should not be repealed. The bill also prohibits the Center for Medicare and Medicaid Innovation from testing any model that would repeal or require a waiver of such restrictions.</summary>
</bill>
